Bunny-line Botox: nasal-bridge movement, off-label status, and nearby function
Bunny lines are often movement-related creases beside the upper nose, but not every mark there is a nasalis wrinkle. BOTOX Cosmetic has no labeled bunny-line indication, and anatomy studies do not prove a predictable cosmetic result.
“Bunny lines” usually refers to creases that appear beside the upper nose with certain facial movements, but a mark in that location is not automatically a nasalis-muscle target. BOTOX Cosmetic does not have a U.S. labeled bunny-line indication. Anatomic research explains why several nearby muscles can contribute to the crease; it is not a site-specific trial proving a predictable cosmetic outcome. The decision starts by observing when the mark appears and what expression the reader wants to preserve.123
Watch the mark move—or not
Ask to compare the area at rest, when smiling, and with the specific nose movement that makes the lines noticeable. A static pigment mark, small surface scar or persistent crease is a different endpoint from a line that appears only with contraction. A provider should not infer the responsible muscle from a single still image. The crow’s-feet guide makes a similar dynamic/static distinction at the eye corner, but nasal-bridge anatomy and adjacent facial function are separate.
| Observation | Why it matters | Useful follow-up |
|---|---|---|
| Line appears with nose scrunch | Movement could contribute | Which movement and muscle are actually involved? |
| Line remains at rest | A static skin finding may also matter | What endpoint is plausible with a movement treatment? |
| Mark is brown, red or raised | Color or surface may not be a muscle effect | Does the clinician identify another cause? |
| Smile or upper-lip function is a priority | Nearby muscles contribute to expression | How is unwanted functional change assessed? |
An original cadaver-and-ultrasound study describes the anatomy behind bunny lines and variation in contributing muscle patterns. It can support the proposition that placement is anatomy-sensitive. It cannot establish that a patient will have a given magnitude or duration of improvement, or that an online injection diagram safely applies to every face. The evidence boundary is worth stating plainly because anatomy papers are often quoted as though they were outcome trials.2
An off-label site is not a new approval
The BOTOX Cosmetic label includes certain frown, lateral-eye, forehead and platysma-band indications. Nasal-bridge bunny lines are not among them. Clinicians may discuss off-label use of an approved drug under their professional judgment, but the label does not provide a bunny-line claim or an endorsed consumer dosing map. “FDA approved Botox” and “FDA approved for my nose lines” are not equivalent statements.13
Ask for the exact product, not merely the word “Botox.” Different botulinum-toxin products are not interchangeable unit for unit, and the plan should account for prior treatment nearby. If a clinician says the lines appeared after treating another facial area, the appropriate question is what changed in movement—not an assumption that adding more toxin in another spot is a correction.
Define success without flattening every expression
A good consultation can name the expression in which the line bothers the reader, the change sought, and what should remain functional. It should include the patient’s baseline asymmetry and whether an effect near the eye, nose or upper lip would be unacceptable. The label’s general safety warnings remain relevant even though this cosmetic site is off-label.1
Interpret a new nasal crease in its timeline
Some people notice bunny lines only after another facial movement changes, including after a previous toxin visit. That timeline deserves to be documented, but temporal order alone does not establish a compensatory muscle mechanism. The clinician can compare baseline photographs, prior treatment sites and the movement that now produces the line. If no prior record exists, the explanation should be offered as a possibility rather than a confident reconstruction of what happened.
Ask whether the mark appears on both sides equally and whether it extends toward the eye or upper cheek. The answer may affect which structure is suspected and which function must be preserved, but it should not become a public placement diagram. Anatomic variation is exactly why the cadaver-and-ultrasound study is informative yet insufficient for a one-size-fits-all dose map. Even a technically accurate diagram cannot tell the operator what that person’s line does in motion.2
The visible change should be assessed under the same expression at baseline and follow-up. If one photograph shows a broad smile and the other a neutral face, no reader can tell whether a movement line improved. A practice that offers treatment should be able to say whether the goal is less folding during a specific expression, not a permanently smooth nasal bridge. Static color or texture could remain even if movement changes.
The exact product, prior toxin exposure, timing and any unwanted eye or upper-lip effect belong in the record. That documentation is useful for later visits even if the person decides against another procedure. It also keeps a site-specific off-label discussion separate from the FDA-approved indications for other facial areas.
Use Treomark’s Botox hub to find a consultation. The most credible answer may be that the visible mark is not primarily a muscle problem.
Sources
- National Library of Medicine DailyMed. BOTOX Cosmetic prescribing information. Current labeled cosmetic treatment sites and warning; nasal-bridge bunny lines are not listed. Accessed .
- Clinical Anatomy. Anatomical etiology of bunny lines based on cadaveric dissection and ultrasonography. Original anatomy and ultrasound evidence about muscle contributions, not an efficacy trial. Accessed .
- U.S. Food and Drug Administration. Understanding unapproved use of approved drugs. Off-label drug use is distinct from an FDA-approved indication. Accessed .